Christensen, James G.

TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors

Edwards, A. C., Stalnecker, C. A., Jean Morales, A., Taylor, K. E., Klomp, J. E., Klomp, J. A., Waters, A. M., Sudhakar, N., Hallin, J., Tang, T. T., et al. (2023) · Cancer Research

Hippo pathway signaling and YAP/TAZProtein Kinase Regulation and GTPase Signaling

Cited by 91

Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRAS G12C -Mutated Non–Small-Cell Lung Cancer Who Have Untreated CNS Metastases

Negrao, M. V., Spira, A. I., Heist, R. S., Jänne, P. A., Pacheco, J. M., Weiss, J., Gadgeel, S. M., Velastegui, K., Yang, W., Der-Torossian, H., et al. (2023) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsBrain Metastases and Treatment

Cited by 85

A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer

Singhal, A., Styers, H. C., Rub, J., Li, Z., Torborg, S. R., Kim, J. Y., Grbovic-Huezo, O., Feng, H., Tarcan, Z. C., Sahin Ozkan, H., et al. (2024) · Cancer Discovery

Pancreatic and Hepatic Oncology ResearchCancer Cells and Metastasis

Cited by 84

99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation

Riely, G. J., Ou, S.-H. I., Rybkin, I., Spira, A., Papadopoulos, K., Sabari, J. K., Johnson, M., Heist, R. S., Bazhenova, L., Barve, M., et al. (2021) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 77

KRYSTAL-1: activity and safety of adagrasib (MRTX849) in patients with colorectal cancer (CRC) and other solid tumors harboring a KRAS G12C mutation

Johnson, M. L., Ou, S. H. I., Barve, M., Rybkin, I. I., Papadopoulos, K. P., Leal, T. A., Velastegui, K., Christensen, J. G., Kheoh, T., Chao, R. C., et al. (2020) · European Journal of Cancer

Colorectal Cancer Treatments and StudiesProtein Kinase Regulation and GTPase Signaling

Cited by 77

Alveolar Differentiation Drives Resistance to KRAS Inhibition in Lung Adenocarcinoma

Li, Z., Zhuang, X., Pan, C.-H., Yan, Y., Thummalapalli, R., Hallin, J., Torborg, S., Singhal, A., Chang, J. C., Manchado, E., et al. (2024) · Cancer Discovery

Lung Cancer Treatments and MutationsCancer Cells and Metastasis

Cited by 74

LBA6 KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation

Weiss, J., Yaeger, R. D., Johnson, M. L., Spira, A., Klempner, S. J., Barve, M. A., Christensen, J. G., Chi, A., Der-Torossian, H., Velastegui, K., et al. (2021) · Annals of Oncology

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 73

Inhibition of c-Met Reduces Lymphatic Metastasis in RIP-Tag2 Transgenic Mice

Sennino, B., Ishiguro-Oonuma, T., Schriver, B. J., Christensen, J. G., & McDonald, D. M. (2013) · Cancer Research

Lymphatic System and DiseasesAngiogenesis and VEGF in Cancer

Cited by 60

KRYSTAL-2: A phase I/II trial of adagrasib (MRTX849) in combination with TNO155 in patients with advanced solid tumors with KRAS G12C mutation.

Sabari, J. K., Park, H., Tolcher, A. W., Ou, S.-H. I., Garon, E. B., George, B., Janne, P. A., Moody, S. E., Tan, E. Y., Sen, S. K., et al. (2021) · Journal of Clinical Oncology

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 50

A phase I/II multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors with KRAS G12C mutation.

Papadopoulos, K. P., Ou, S.-H. I., Johnson, M. L., Christensen, J., Velastegui, K., Potvin, D., Faltaos, D., & Chao, R. C. (2019) · Journal of Clinical Oncology

Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations

Cited by 37

A Transient Pseudosenescent Secretome Promotes Tumor Growth after Antiangiogenic Therapy Withdrawal

Mastri, M., Tracz, A., Lee, C. R., Dolan, M., Attwood, K., Christensen, J. G., Liu, S., & Ebos, J. M. L. (2018) · Cell Reports

Angiogenesis and VEGF in CancerTelomeres, Telomerase, and Senescence

Cited by 28

P-71 KRYSTAL-10: A randomized phase 3 study of adagrasib (MRTX849) in combination with cetuximab vs chemotherapy in patients with previously treated advanced colorectal cancer with KRASG12C mutation

Tabernero, J., Bendell, J., Corcoran, R., Kopetz, S., Lee, J., Davis, M., Christensen, J., Chi, A., Kheoh, T., & Yaeger, R. (2021) · Annals of Oncology

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 28

Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients

Paweletz, C. P., Heavey, G. A., Kuang, Y., Durlacher, E., Kheoh, T., Chao, R. C., Spira, A. I., Leventakos, K., Johnson, M. L., Ou, S.-H. I., et al. (2023) · Clinical Cancer Research

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 23

Abstract LB-C09: the KRASG12C inhibitor MRTX849 reconditions the tumor immune microenvironment and leads to durable complete responses in combination with anti-PD-1 therapy in a syngeneic mouse model

Briere, D. M., Calinisan, A., Aranda, R., Sudhakar, N., Hargis, L., Gatto, S., Fernandez-Banet, J., Pavlicek, A., Engstrom, L. D., Hallin, J., et al. (2019) · Molecular Cancer Therapeutics

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 13

Abstract LB002: Mechanisms of acquired resistance to KRAS G12C inhibition in cancer

Awad, M., Liu, S., Arbour, K., Zhu, V., Johnson, M., Heist, R., Patil, T., Riely, G., Jacobson, J., Dilly, J., et al. (2021) · Cancer Research

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 12

Impact of STK11 mutation on first-line immune checkpoint inhibitor (ICI) outcomes in a real-world KRAS G12C mutant lung adenocarcinoma cohort.

Heist, R. S., Yu, J., Donderici, E. Y., Zhang, N., Espenschied, C. R., Lang, K., Korytowsky, B., Chi, A. S., & Christensen, J. G. (2021) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 12

Abstract B30: Structure-based drug discovery of MRTX1257, a selective, covalent KRAS G12C inhibitor with oral activity in animal models of cancer

Marx, M. A., Baer, B. R., Ballard, J., Blake, J. F., Bouhana, K., Briere, D. M., Burgess, L. E., Burkhard, M. R., Chiang, H., Chicarelli, M. J., et al. (2020) · Molecular Cancer Research

Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

Cited by 11

Abstract LB-098: The anti-tumor activity of the KRAS G12C inhibitor MRTX849 is augmented by cetuximab in CRC tumor models

Hallin, J., Calinisan, A., Hargis, L., Aranda, R., Engstrom, L. D., Briere, D. M., Marx, M. A., Olson, P., & Christensen, J. G. (2020) · Cancer Research

Colorectal Cancer Treatments and StudiesProtein Kinase Regulation and GTPase Signaling

Cited by 2

Supplementary Figure 4 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

Yaeger, R., Mezzadra, R., Sinopoli, J., Bian, Y., Marasco, M., Kaplun, E., Gao, Y., Zhao, H., Paula, A. D. C., Zhu, Y., et al. (2023)

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 0